p53 protein detected by immunohistochemical staining is not always mutant.

The expression of the tumour suppressor gene p53 was analyzed in a variety of human solid tumours by immunohistochemistry and direct DNA sequencing. Positive nuclear staining using a panel of anti-p53 antibodies was used to select tumours for further genetic analysis. Using PCR amplification followed by immobilization onto magnetic beads and direct sequencing, we sequenced exons 5-9 of the p53 gene from 9 melanomas, 8 nasopharyngeal carcinomas, 16 sporadic breast carcinomas and 11 patients from familial breast cancer families. No sequence alterations of the p53 gene were detected in either the melanoma or nasopharyngeal tumours and only 19% of the primary breast carcinomas showed a variant band indicative of a mutation. Our results indicate firstly that p53 mutations are not generally involved in the tumour types studied and secondly the data emphasize the disparity encountered when attempting to correlate p53 immunohistochemical positivity with mutations within the p53 gene.

[1]  J. Farndon,et al.  Correlation between p53 mutations and antibody staining in breast carcinoma , 1993, The British journal of surgery.

[2]  N. Lassam,et al.  Overexpression of p53 is a late event in the development of malignant melanoma. , 1993, Cancer research.

[3]  D. Barnes,et al.  Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? , 1993, Human pathology.

[4]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[5]  Scott W. Lowe,et al.  p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.

[6]  H. J. Evans,et al.  p53 mutations in breast cancer. , 1992, Cancer research.

[7]  A. Yang,et al.  Absence of p53 gene mutations in primary nasopharyngeal carcinomas. , 1992, Cancer research.

[8]  D. Lane,et al.  Abnormal expression of wild type p53 protein in normal cells of a cancer family patient , 1992, The Lancet.

[9]  A. Levine,et al.  Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[10]  N. Colburn,et al.  An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[11]  C. Theillet,et al.  p53 mutations occur in aggressive breast cancer. , 1992, Cancer research.

[12]  P. Friedman,et al.  Wild-type p53 activates transcription in vitro , 1992, Nature.

[13]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[14]  P. Meltzer,et al.  Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.

[15]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[16]  T. Tursz,et al.  Alterations of the p53 gene in nasopharyngeal carcinoma , 1992, Journal of virology.

[17]  B. Vogelstein,et al.  Inherited p53 gene mutations in breast cancer. , 1992, Cancer research.

[18]  D. Wynford‐Thomas.  P53 in tumour pathology: Can we trust immunocytochemistry? , 1992, The Journal of pathology.

[19]  B. Ponder,et al.  No evidence for germline mutations in exons 5-9 of the p53 gene in 25 breast cancer families. , 1992, Oncogene.

[20]  J. Simon,et al.  A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Merlo,et al.  Mutations in the p53 gene in primary human breast cancers. , 1991, Cancer research.

[22]  D. Carbone.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa Bressac B, Kew M, Wands J, Ozturk M. Nature 1991;350:429?431 , 1991 .

[23]  J. Bartek,et al.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. , 1991, Oncogene.

[24]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[25]  J. Marks,et al.  Genetic basis for p53 overexpression in human breast cancer. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Wands,et al.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa , 1991, Nature.

[27]  W. J. Brammar,et al.  Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. , 1991, Oncogene.

[28]  T. Soussi,et al.  Structural aspects of the p53 protein in relation to gene evolution. , 1990, Oncogene.

[29]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[30]  W. Maltzman,et al.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.

[31]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[32]  J. Waterhouse.  Cancer incidence in five continents, v.3 , 1976 .

[33]  R. W. Scarff,et al.  Histological typing of breast tumors. , 1982, Tumori.

[34]  H. Bloom,et al.  Histological Grading and Prognosis in Breast Cancer , 1957, British Journal of Cancer.

[35]  A. Davidoff,et al.  Genetic basis for p 53 overexpression in human breast cancer ( protein expression / gene mutation / alielic deletion ) , 2022 .